On August 30, 2021 Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical-stage cell therapy company, reported the appointment of current Chief Operating Officer, Jennifer Chow, as Chief Executive Officer and Managing Director (Press release, Chimeric Therapeutics, AUG 30, 2021, View Source [SID1234587227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ms Chow has been Chief Operating Officer of Chimeric since November 2020. Prior to joining Chimeric, Ms Chow was Head of Global Marketing, Analytics and Commercial Operations at leading global CAR T company Kite Pharmaceuticals (acquired by Gilead Sciences in 2017 for US$12 billion). Ms Chow was responsible for assessing and prioritizing research and external assets for development, ensuring optimal clinical development of the Kite pipeline for global commercialisation.

Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, hematology and oncology. She was previously Global Cell Therapy Commercial Lead at Celgene Corporation and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed/Takeda and Schering Canada.

"We are delighted to announce the appointment of Jennifer as MD & CEO. During her time with Chimeric thus far as COO, Jennifer has demonstrated outstanding dedication and leadership while importantly proving to be exceedingly knowledgeable in the field of cell therapy," said Paul Hopper, Executive Chairman, Chimeric Therapeutics.

"The team we’ve been able to assemble at Chimeric brings deep scientific & commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership."

For the purpose of ASX Listing Rule 3.16.4, a summary of the material terms of Ms Chow’s employment agreement is set out in appendix 1.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.